Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Raises Bar for New Drugs, Manufacturers
With Tougher CMC Reviews, GMP Inspections

This article was originally published in The Gold Sheet

Executive Summary

As Asian drug regulatory authorities gain confidence in their ability to regulate new drug products, they are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe.
Advertisement

Related Content

ICH Enhances Regulators’ Roles While Preserving Industry Access
BRIC Nations Slow to Join PIC/S Inspection Coordination Effort
‘Global Allegiance’ of Inspectorates Emerging
WHO Revises Zone IV Stability Guideline

Topics

Advertisement
UsernamePublicRestriction

Register

PS000565

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel